Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Alzheimer's and Dementia

Volumn 8, Issue 4, 2012, Pages 295-303

  Li, Jinhe ^a   Llano, Daniel A ^a   Ellis, Teresa ^a   Leblond, David ^a   Bhathena, Anahita ^a   Jhee, Stanford S ^b   Ereshefsky, Larry ^b,c   Lenz, Robert ^a   Waring, Jeffrey F ^a  

^a ABBOTT LABORATORIES   (United States)

^b PAREXEL INTERNATIONAL   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biomarker; Cerebrospinal fluid; Clinical trial

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL STUDY; HUMAN; LUMBAR PUNCTURE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STUDY DESIGN;

ADULT; AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 84863188619     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.05.900     Document Type: Article

References (22)

1. D.A. Evans, H.H. Funkenstein, M.S. Albert, P.A. Scherr, N.R. Cook, M.J. Chown, L.E. Hebert, C.H. Hennekens, and J.O. Taylor Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported JAMA 262 1989 2551 2556
2. P.K. Molsa, R.J. Marttila, and U.K. Rinne Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia Acta Neurol Scand 91 1995 159 164
3. D.M. Walsh, and D.J. Selkoe Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 44 2004 181 193 (Pubitemid 39348839)
4. D.J. Selkoe Normal and abnormal biology of the beta-amyloid precursor protein Annu Rev Neurosci 17 1994 489 517 (Pubitemid 24117040)
5. F. Hernández, and J. Avila Tauopathies Cell Mol Life Sci 64 2007 2219 2233 (Pubitemid 47347961)
6. T. Sunderland, G. Linker, N. Mirza, K.T. Putnam, D.L. Friedman, and L.H. Kimmel Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103 (Pubitemid 37430211)
7. M. Citron Alzheimer's disease: strategies for disease modification Nat Rev Drug Discov 9 2010 387 398
8. I. Melnikova Therapies for Alzheimer's disease Nat Rev Drug Discov 6 2007 341 342 (Pubitemid 46696548)
9. A. Extance Alzheimer's failure raises questions about disease-modifying strategies Nat Rev Drug Discov 9 2010 749 751
10. E. Siemers, M. Skinner, R.A. Dean, C. Gonzales, J. Satterwhite, M. Farlow, D. Ness, and P.C. May Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers Clin Neuropharmacol 28 2005 126 132 (Pubitemid 40923411)
11. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, and R.A. Dean Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol 65 2008 1031 1038
12. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 2008 779 786
13. S. Sankaranarayanan, M.A. Holahan, D. Colussi, M.C. Crouthamel, V. Devanarayan, and J. Ellis First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates J Pharmacol Exp Ther 328 2009 131 140
14. L.M. Shaw Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics Nat Rev Drug Discov 6 2007 295 303 (Pubitemid 46505880)
15. L.J. Thal, K. Kantarci, E.M. Reiman, W.E. Klunk, M.W. Weiner, and H. Zetterberg The role of biomarkers in clinical trials for Alzheimer disease Alzheimer Dis Assoc Disord 20 2006 6 15 (Pubitemid 44356888)
16. R.J. Bateman, G. Wen, J.C. Morris, and D.M. Holtzman Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker Neurology 68 2007 666 669 (Pubitemid 46667813)
17. J.E. Kang, M.M. Lim, R.J. Bateman, J.J. Lee, L.P. Smyth, J.R. Cirrito, N. Fujiki, S. Nishino, and D.M. Holtzman Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle Science 326 2009 1005 1007
18. H. Zetterberg, M. Pedersen, K. Lind, M. Svensson, S. Rolstad, and C. Eckerström Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years J Alzheimers Dis 12 2007 255 260 (Pubitemid 350179256)
19. J.L. Fleiss The design and analysis of clinical experiments 1986 John Wiley & Sons New York, NY p. 396-71
20. G. Tong, L. Castaneda, J.S. Wang, A. Sverdlov, S.P. Huang, and R. Slemmon A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men Alzheimers Dement 6 2010 S143
21. G. Bissette Does Alzheimer's disease result from attempts at repair or protection after transient stress? J Alzheimers Dis 18 2009 371 380
22. R.J. Bateman, L.Y. Munsell, J.C. Morris, R. Swarm, K.E. Yarasheski, and D.M. Holtzman Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo Nat Med 12 2006 856 861 (Pubitemid 44050079)